Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis

Joint Bone Spine

Volumn 77, Issue 1, 2010, Pages 53-57

  Fardellone, Patrice ^a   Cortet, Bernard ^b   Legrand, Erick ^c   Bresse, Xavier ^d   Bisot Locard, Ségolène ^d   Vigneron, Anne Marie ^d   Beresniak, Ariel ^e,f  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d NOVARTIS PHARMA K K   (Japan)

^e et Institut de recherche et documentation en économie de la santé   (France)

^f DATA MINING INTERNATIONAL   (Switzerland)

Author keywords

Adherence; Cost effectiveness; Modelling; Postmenopausal osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ARTICLE; DRUG COST; DRUG EFFICACY; FRAGILITY FRACTURE; HEALTH CARE COST; HIP FRACTURE; HUMAN; INTERMETHOD COMPARISON; PATIENT COMPLIANCE; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; SIMULATION; TREATMENT PLANNING; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; MODELS, ECONOMETRIC; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 73449107105     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.04.009     Document Type: Article

References (38)

1. Cranney A., Jamal S., Tsang J., et al. Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177 (2007) 575-580
2. Reginster J., Rabenda V., and Neuprez A. Adherence, patient preference and dosing frequency: Understanding the relationship. Bone 38 (2006) S4-9
3. Rabenda V., Manette C., Lemmens R., et al. The direct and indirect costs of the chronic management of osteoporosis: A prospective follow-up of 3440 active subjects. Osteoporos Int 17 (2006) 1346-1352
4. Kanis J., and Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16 (2005) 229-238
5. O'Neill T. The prevalence of vertebral deformity in European men and women: The European vertebral osteoporosis study. J Bone Miner Res 11 (1996) 1010-1018
6. DGS G. Ostéoporose. 2003; Mise à jour.
7. Maravic M., Le Bihan C., Landais P., et al. Incidence and cost of osteoporotic fracture in France during 2001. A methodological approach by the National Hospital Database. Osteoporosis Int 16 (2005) 1475-1480
8. Lekkerkerker F., Kanis J., Alsayed N., et al. Adherence to treatment of osteoporosis: A need for study. Osteoporos Int 18 (2007) 1311-1317
9. Hadji P., Minne H., Pfeifer M., et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis. A randomised crossover study (BALTO II). Joint Bone Spine 75 (2008) 303-310
10. Maricic M. New and emerging treatments for osteoporosis. Curr Opin Rheumatol 19 (2007) 364-369
11. Briesacher B., Andrade S., and Kahler K. Economic impact of the previous year's adherence with bisphosphonates. J Bone Miner Res 21 (2006) S171
12. Tosteson A., Jönsson B., Grima D., et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12 (2001) 849-857
13. Fleurence R., Iglesias C., and Johnson J. The cost-effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: A structured review of the literature. Pharmacoeconomics 25 (2007) 913-933
14. Kanis J., Burlet N., Cooper C., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19 (2008) 399-428
15. Black D., Cummings S., Karpf D., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348 (1996) 1535-1541
16. Cummings S., Black D., Thompson D., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial. JAMA 280 (1998) 2077-2082
17. Reginster J., Minne H., Sorensen O., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11 (2000) 83-91
18. McClung M., Geusens P., Miller P., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 344 (2001) 333-340
19. Chesnut I., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
20. Siris E., Adachi J., Lu Y., et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: Results from the more study. Multiple outcomes of raloxifene evaluation. Osteoporos Int 13 (2002) 907-913
21. Meunier P., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
22. Reginster J., Seeman E., De Vernejoul M., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90 (2005) 2816-2822
23. Neer R., Arnaud C., Zanchetta J., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
24. Huybrechts K., Ishak K., and Caro J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 (2006) 922-928
25. Briesacher B., Andrade S., Yood R., et al. Consequences of poor compliance with bisphosphonates. Bone 41 (2007) 882-887
26. Black D., Schwartz A., Ensrud K., et al. Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (flex): A randomized trial. JAMA 296 (2006) 2927-2938
27. Watts N., Chines A., Olszynski W., et al. Watts nb, fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19 (2008) 365-372
28. Finnern H., and Syke D. The hospital cost of vertebral fractures in the EU: Estimates using the national datasets. Osteoporosis Int (2003) 14
29. Bouee S., Lafuma A., Fagnani F., et al. Estimation of direct unit costs associated with non vertebral osteoporotic fractures in five European countries. Rheumatol Int 26 (2006) 1063-1072
30. Siris E., Harris S., Rosen C., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
31. Cramer J., Lynch N., Gaudin A., et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28 (2006) 1686-1694
32. Cortet B., and Benichou O. Adherence, persistence, concordance: Do we provide optimal management to our patients with osteoporosis?. Joint Bone Spine 73 (2006) e1-e7
33. Weycker D., Macarios D., Edelsberg J., et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17 (2006) 1645
34. Cotté F., Cortet B., Lafuma A., et al. A model of the public health impact of improved treatment persistence in postmenopausal osteoporosis in France. Joint Bone Spine (2007)
35. Beresniak A., Russell A., Haraoui B., et al. Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 34 (2007) 2193-2200
36. Levy E., Auray J., Bail J., et al. Guidelines and recommendations for French pharmacoeconomic studies. J Econ Med 16 (1998) 353-372
37. Black D. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
38. Doherty S., Goodby A., and Steel S. Compliance and effect of bone protective treatment in elderly females: 5-year follow-up study. Rheumatology 44 (2005) i34